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INTRODUCTION
Oxidative stress is an imbalance resulting from increased pro-
oxidant generation and/or decreased anti-oxidant defenses. It
is implicated in the pathogenesis of various diseases, such as
atherosclerosis, diabetes, hemochromatosis, ischemic
reperfusion injury, and rheumatoid arthritis, and in the normal
aging process (Loeckie et al., 1999).  Increased oxidative stress
in type 2 diabetes is a complex process which results from the
abnormalities in the metabolic pathway. Hyperglycemia can
increase oxidative stress through several pathways. Nishikawa
et al. (2000) have shown that hyperglycemia induced
overproduction of mitochondrial superoxide promotes the
formation of advanced glycosylation end products, Protein
kinase -C activation and hexosamine pathway activity. Lipid
peroxidation induced by oxidants and oxidative stress,
generates a huge variety of lipid peroxidation products,
including reactive carbonyl compounds [RCCs] (Negre-
Salvayre et al., 2008). RCCs such as aldehydes and
dicarbonyls, including hydroxyalkenals, acrolein,
malondialdehyde (MDA), glyoxal and methylglyoxal, exhibit
a large panel of biological properties. These aldehydes react
on cellular and tissue proteins to form advanced lipid end
products (ALEs) that induce protein dysfunctions and alter
cellular responses (Petersen and Doorn, 2004). One of the
best-known effects of ALEs precursors is their role in the
modification of LDLs which is involved in the formation of
early atherosclerotic lesions (Chisolm and Steinberg, 2000).
For many years, lipid oxidation has been the focus of
investigation, but due to their relatively high abundance, it is
now recognized that proteins are the main targets for
oxidation. The oxidation of protein plays a key role in the
pathogenesis of degenerative and cancer diseases (Olas et
al., 2008). Advanced oxidation protein products (AOPPs) were
first described by Witko-Sarsat et al., (1996) and are formed
during oxidative stress by the action of chlorinated oxidants,
mainly hypochlorous acid and chloramines (Mcgarrigle et
al., 2007). AOPPs are defined as dityrosine containing cross
linked protein products and are considered to be reliable
markers to estimate the degree of oxidant mediated protein
damage. These products originate as a result of the action of
free radicals on proteins and may act as inflammatory
mediators triggering the oxidative ignition of neutrophiles,
monocytes, and T- lymphocytes, thus leading to upregulation
and excessive stimulation of dendritic cells (Kalousova  et al.,
2002).
Paraoxonase-1 (PON1) is a protein of 354 amino acids with a
molecular mass of 43 kDa (Primo-Parma et al., 1996). Human
PON1 is synthesized in the liver and secreted into the blood
and is associated exclusively with HDLs in the serum
(Mackness, 1989). Human serum PON1 has been implicated
in the detoxification of organophosphates, and possibly in
the prevention of lipid peroxidation of low-density lipoprotein
(Mackness et al., 2000). It has been shown that human serum
paraoxonase activity is a predictor of coronary artery disease
[CAD] (Mackness et al., 2003). PON1 reduces oxidized lipids
in human atherosclerotic lesions derived from carotid or
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coronary artery specimens (Aviram et al., 2000). PON1 directly
inhibits macrophage oxidative stress and therefore, decreasing
the ability of macrophages to release superoxide anions and
to oxidize LDL (Rozenberg et al., 2003). Reduced paraoxonase
activities have been reported in several groups of patients
with diabetes, hypercholesterolemia and cardiovascular
disease who are under increased oxidative stress (Mackness
et al., 1991; Ayub et al., 1999). There are no reports on the
AOPP and its relation with PON 1 and lipid peroxide in type
2 diabetes.  Hence, the present study was undertaken to
evaluate the AOPP, lipid peroxide marker and PON 1 activity
in type2 diabetic patients as well as to study the relation between
them and other biochemical markers.
MATERIALS AND METHODS
Study population
All the studies were carried out at The Department of
Biochemistry, Bangalore University, Bangalore. The study
population were identified and conducted in the KC General
hospital, Bangalore. The study population included 120
subjects, out of them 60 are non-diabetic healthy control
without any symptoms of acute inflammation and the other
60 are patients with type 2 diabetes mellitus with a mean
disease duration of 3.91± 3.53 years. All the diabetic patients
were on treatment with oral hypoglycemic agents. All patients
were in a stable clinical condition without any symptoms of
acute infection. All subject were questioned and informed
about the aim of the study and their consent has been obtained.
Ethical clearance for this study has been obtained from the
ethical Committee of the Institution. The clinical and general
biochemical characteristics of the study population are shown
in Table 1. Blood was collected after an overnight fasting from
the antecubital vein. 3mL blood was transferred to EDTA added
tubes for estimation of HbA
1c
. The serum for analysis was
obtained by collecting blood in a plain vacutainer and
centrifuged at 3000 rpm for 15 minutes after keeping for 30
min at room temperature.  The sera so obtained was stored at
–70ºC.
Biochemical tests
Glucose, lipids and lipoproteins were estimated using
enzymatic-colorimetric kits (ERBA Diagnostic Mannheim
GmbH). LDL cholesterol was calculated using Friedewald
formula (Friedewald et al., 1972). HbA
1c
 was estimated using
ion exchange resin method (Coral Clinical System kit).
Estimation of AOPP
The concentration of AOPP in the serum samples was
determined by the spectrophotometric method of Witko- Sarsat
et al., (1996). The method is based on the color reaction of
AOPP with potassium iodide solution in an acidic
environment. 100μL of biological material was diluted to 1.0
mL with phosphate buffered saline. Then, 50 μL of 1.16M
potassium iodide solution followed by 100μL 10% acetic acid
were added. The absorbance of the solution was measured
immediately at 340 nm against a suitable blank. The
concentrations of AOPP were express as chloramines-T units
(μmol/L).
Estimation of PON1 activity
PON1 arylesterase activity was measured
spectrophotometrically according to the method of Gan et al.,
(1991) with a slight modification. The assay mixture contained
2 mM of phenylacetate in 50 mM Tris–HCl buffer (pH 8.0)
containing 2 mM of calcium chloride. The reaction was started
by the addition of serum and the increase in the absorbence
was recorded at 270 nm. Blanks were included to correct for
the spontaneous hydrolysis of phenylacetate. The
concentration of phenol formed was calculated by using 1.310
M-1 cm-1 as the molar extinction coefficient of phenol. One
unit of arylesterase activity is defined as the amount of enzyme
required to release 1 μmole of phenol per minute. The total
activity is expressed as μmol / mL.
Estimation of MDA
MDA in the serum samples was estimated using Buege and
Aust’s method (1978). Serum samples were mixed with
thiobarbituric acid (TBA) reagent (0.375% TBA, 15%TCA in
0.25 N HCl) and boiled for 10 min. After cooling, 2.0 mL of
0.2 N NaOH was added and vortexed for 10 min. Then the
samples were centrifuged and the absorbances of the
supernatants were measured at 533 nm against a suitable
blank. MDA concentration was calculated using a molar
extinction coefficient of 156 M-1 cm-1 and expressed as nmol/
mL.
Statistical analysis
All analysis were performed by using statistical software SPSS.
Independent-sample t-tests were performed in the analysis of
biochemical data. Two tailed probability (P) value were
calculated and a value of p<0.05 was considered as
statistically significant. The correlation coefficient was
calculated using Bivariate correlation method.
RESULTS
The biochemical characteristics of healthy control and type 2
diabetes study subjects are given in Table 1. The plasma lipid
profile of type 2 diabetic patients showed a significant elevated
level of T.C., T.G., LDL-C (p<0.05), while HDL-C appeared to
be reduced (p<0.05). The levels of AOPP, MDA and PON 1
activity in control and diabetic group is tabulated in Table 2.
The marker of oxidative stress AOPP and MDA were signifi-
cantly higher in the serum of type 2 diabetes compared to
control (p<0.05). On other hand, PON 1 level was found to
be low in the patients with type 2 diabetes compared to con-
trol (p<0.05). The correlation analysis data between AOPP,
PON1, MDA, HbA
1c
 and diabetic period in patient with type 2
diabetes is summarized in Table 3. The results showed  sig-
nificant  positive correlation between AOPP with MDA (r=
0.306*) and HbA
1c
 (r=0.275*) whereas, there was  no signifi-
cant correlation found between AOPP with PON1 and dia-
betic period in the subjects with type 2 diabetes .  PON 1 level
showed a negative correlation with MDA (r= −0.602**),
HbA1c (r = −0.602**) and with diabetic period (r= −0.372**).
The MDA level showed a positive correlation with HbA
1c
 (r=−
0.571**) and with diabetic period (r= − 0.372**). The corre-
lation analysis data of diabetic group between AOPP and PON
1 is shown in Fig.1 and AOPP and MDA in Fig. 2. The data
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indicated a negative correlation between AOPP and PON 1
level and is not significant.  However, when analysis was done
between AOPP and MDA, there was a positive correlation
which is significant. The present   study   found    no   signifi-
cant difference in the level of AOPP, PON1and MDA of the
study population when the data was analyzed according to
the diet (Table 4).
DISCUSSION
Oxidative stress is thought to be increased in a system where
the rate of free radical production is increased and/or the
antioxidant mechanisms are impaired. In recent years, the
oxidative stress-induced free radicals have been implicated
in the pathology of type-1 and type-2 diabetic patients
(Brownlee et al., 1986; Ashour et al., 1999). The present study
is undertaken to assess the AOPPs and their possible relation
with PON1 activity and lipid peroxide in type 2 diabetes pa-
tients.  Hyperglycemia in diabetic patients can increase the
levels of free radicals through glucose autooxidation. This leads
to non-enzymatic post-translational glycation of proteins re-
sulting from chemical reaction between glucose and primary
amino groups of proteins and also through polyol pathway
and protein kinase activation (Forbes et al., 2004, Tsai et al.,
1994). Our study showed significant increase in protein oxi-
dation and lipid peroxidation as reflected by increase in the
plasma level of AOPP, a marker of protein oxidation and MDA
a marker of lipid peroxidation. The increase in protein oxida-
tion and lipid peroxidation in diabetics in the present study
are in accordance with earlier findings that hyperglycemia in-
duces overproduction of oxygen free radicals in diabetes
(Nourooz-Zadeh et al., 1997; Vanizor et al., 2001; Pasaoglu
et al., 2004). Witko-Sarsat et al. (1996) have reported an in-
crease in the level of AOPP in hemodialyzed patients without
differences between diabetics and non-diabetics. AOPP was
reported to be elevated in patients with CAD and considered
to be independent risk factor for CAD status (Kaneda et al.,
2002). Moreover, lipoperoxidation of cellular components, a
consequence of free-radical activity, is thought to play an im-
portant role in aging, atherosclerosis, and late complications
of diabetes (Kesavulu et al., 2001). The level of PON1, the
anti-oxidative and anti-atherogenic enzyme was found to de-
crease in patients with type 2 diabetes compared to control
(p<0.05). The decreased level of PON1 activity in type 2 dia-
betes may result in part from increased HDL-C glycation
underglycemic stress. It has been reported that increased
glycation of HDL leads to the impairment of its anti-atheroscle-
rotic properties (Hedrick et al., 2000). In vitro glycation of
HDL appears to partially inhibit PON1 (Feretti et al., 2001). It
also has been reported that PON 1 is heavily glycated in vivo
in people with type 2 diabetes and those with coronary heart
desease which appears to inhibit PON 1’s ability to metabo-
lize membrane lipid hydroperoxides (Mastorikou et al., 2008).
Serum PON 1 activity was also shown to be decreased in
Table 3: Correlation analysis of AOPP, PON1, MDA, HbA
1c
, and
diabetic period in the patients with type 2 diabetes
Parameters analyzed r p Value
AOPP / PON1 − 0.206 0.114
AOPP / MDA 0.306* 0.017
AOPP /diabetic period 0.233 0.073
AOPP / HbA
1c
0.275* 0.034
PON1 / MDA −0.602** 0.000
PON1 / HbA
1c
−0.602** 0.000
PON1 / diabetic period −0.509** 0.000
MDA / HbA
1c
0.571** 0.000
MDA / diabetic period 0.372** 0.003
**Correlation is significant at the 0.01 level (2-tailed);  *Correlation is significant at the
0.05 level (2-tailed)
Table 2: Serum levels of AOPP, MDA and PON 1 in control and
diabetic groups
Parameters Control Diabetic Significance
n =60 group n =60
AOPP μmoL/L 65.95 ± 21.769 103.38 ± 33.49 p<0.05
MDA nmoL/mL  2.56 ± 0.764  3.27 ± 1.097 p<0.05
PON1 μmoL/mL 93.33 ± 29.108  69.03 ± 21.55 p<0.05
The result are expressed as mean ± SD
Table 1: Clinical and Biochemical characteristics of the control and type 2 diabetic subjects
parameter Control Diabetic group Significance
Total No. 60 60
Age (Year) 49 ± 12 52 ± 10 p=0.150
Gender(M/F) 28 / 32 29 / 31
MBI (Kg/m2) 26.3 ± 4.4 27.2 ± 3.5 p= 0.191
Blood pressure Diastolic Systolic 84.6 ± 12.1127.3 ± 16.8 85.5 ± 10.5130.6 ± 15.4 p=0.688p=0.259
FBS (mg/dL) 86.8 ± 12.4 123.9 ± 23.4 p<0.05
Cholesterol (mg/dL) 202.38 ± 15.91 225.60 ± 32.49 p<0.05
Triglyceride (mg/dL) 160.53 ± 25.76 196.91 ± 61.71 p<0.05
LDL (mg/dL) 118.88 ± 17.87 140.83 ± 32.80 p<0.05
HDL (mg/dL) 51.98 ± 7.08 44.78 ± 9.66 p<0.05
HbA
1c
 ( %) 7.91 ± 1.83
Diabetic period (Year) 3.91 ± 3.53
The result are expressed as mean ± SD
OXIDATIVE STRESS PRODUCTS
Table 4: Comparison of serum levels of PON1, AOPP, and MDA in vegetarian and non-vegetarian subjects
Parameter Vegetarian (n=30) Non-vegetarian (n=90)  p value
PON1 μmoL/mL 76.30 ± 29.55 82.81 ± 27.80 0.276
AOPP μmoL/L 93.53 ± 32.41 81.71 ± 33.96 0.098
MDA nmoL/mL  3.00 ± 1.04  2.89 ± 1.00 0.632
The results are expressed as mean ± SD
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patients after myocardial infarction (McElveen et al., 1986), in
patients with familial hypercholesterolemia (Kaneda et al.,
2002), and in patients with diabetes mellitus (Mackness et al.,
1991) in comparison to healthy subjects. Our study also indi-
cates that there is a significant positive correlation between
AOPP with MDA (r= 0.306*) and HbA
1c
 (r = 0.257*) in the
diabetic patient. This correlation seems to indicate the role of
hyperglycemic inducing lipid peroxidation and protein oxi-
dation. Many reports have appeared supporting the idea that
protein and lipid oxidation are coupled processes. On the
other hand, the interaction between lipids and proteins dur-
ing oxidation is not well understood. The relationship be-
tween AOPPs and PON1 activity is not completely under-
stood. In the present study, the correlation between AOPPs
and PON1 activity in type 2 diabetic subjects was not found
to be statistically significant (r = -0.206 p=0.114). In contrast,
PON1 activity was found to be negatively correlated with MDA
and HbA
1c
 (r= -0.602 p=0.000). PON1 was also significantly
correlated with diabetic duration (r= -0.509 p=0.000). The
significant elevation of MDA in type 2 diabetic patient indi-
cates an increase in the lipid peroxidation. MDA reacts with
Lys residues by forming Schiff bases and plays a major role in
low-density lipoprotein (LDL) modification and their metabolic
deviation towards macrophages (Raziel et al., 2001). Oxida-
tion of LDL lipids is thought to render the lipoprotein athero-
genic, because oxidized LDL is more readily taken up by mac-
rophages via scavenger receptors. Paraoxonase is an esterase
residing on high-density lipoprotein. The antioxidant activity
of HDL is largely due to PON1. The enzyme has found to
protect both HDL and low-density lipoproteins (LDL) against
peroxidation, which suggests a possible involvement of PON1
in the anti-atherogenic properties of HDL. It has been shown
that in vitro purified paraoxonase decreased LDL lipid
peroxidation (Durrington et al., 1991) and that purified
paraoxonase significantly reduced the ability of mildly oxi-
dized LDL to induce monocyte endothelial interactions. All
these findings substantiates the negative correlation between
PON1 with MDA and oxidative stress. The oxidative stress
induced through many pathways  are associated with decrease
of PON1 activity in type 2 diabetes as well as increase in the
severity of diabetic complications . Inactivation of PON1 itself
may lead to a predisposition to atherosclerosis as well as in-
creased markers of oxidative stress. The increase in the level
of T.C., T.G., LDL (p=0.000) with a decrease in the level of
HDL observed in the present study are also implicated in the
oxidative stress and pathogenesis of the diabetes mellitus.
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